Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season
Abstract
:1. Introduction
2. Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Li, Y.; Wang, X.; Blau, D.M.; Caballero, M.T.; Feikin, D.R.; Gill, C.J.; Madhi, S.A.; Omer, S.B.; Simões, E.A.F.; Campbell, H.; et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis. Lancet 2022, 399, 2047–2064. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.; Li, Y.; Shi, T.; Bont, L.J.; Chu, H.Y.; Zar, H.J.; Wahi-Singh, B.; Ma, Y.; Cong, B.; Sharland, E.; et al. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: A systematic review and meta-analysis of aggregated and individual participant data. Lancet 2024, 403, 1241–1253. [Google Scholar] [CrossRef]
- Wildenbeest, J.G.; Billard, M.N.; Zuurbier, R.P.; Korsten, K.; Langedijk, A.C.; van de Ven, P.M.; Snape, M.D.; Drysdale, S.B.; Pollard, A.J.; Robinson, H.; et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: A prospective birth cohort study. Lancet Respir. Med. 2023, 11, 341–353. [Google Scholar] [CrossRef]
- Lin, G.L.; Drysdale, S.B.; Snape, M.D.; O’Connor, D.; Brown, A.; MacIntyre-Cockett, G.; Mellado-Gomez, E.; de Cesare, M.; Ansari, M.A.; Bonsall, D.; et al. Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus. Nat. Commun. 2024, 15, 2379. [Google Scholar] [CrossRef] [PubMed]
- Hak, S.F.; Venekamp, R.P.; Billard, M.N.; van Houten, M.A.; Pollard, A.J.; Heikkinen, T.; Cunningham, S.; Millar, M.; Martinón-Torres, F.; Dacosta-Urbieta, A.; et al. Substantial Burden of Nonmedically Attended RSV Infection in Healthy-Term Infants: An International Prospective Birth Cohort Study. J. Infect. Dis. 2024, 229 (Suppl. S1), S40–S50. [Google Scholar] [CrossRef] [PubMed]
- Bosis, S.; Esposito, S.; Niesters, H.G.; Crovari, P.; Osterhaus, A.D.; Principi, N. Impact of human metapneumovirus in childhood: Comparison with respiratory syncytial virus and influenza viruses. J. Med. Virol. 2005, 75, 101–104. [Google Scholar] [CrossRef]
- Bianchini, S.; Silvestri, E.; Argentiero, A.; Fainardi, V.; Pisi, G.; Esposito, S. Role of Respiratory Syncytial Virus in Pediatric Pneumonia. Microorganisms 2020, 8, 2048. [Google Scholar] [CrossRef] [PubMed]
- Jefferies, K.; Drysdale, S.B.; Robinson, H.; Clutterbuck, E.A.; Blackwell, L.; McGinley, J.; Lin, G.L.; Galal, U.; Nair, H.; Aerssens, J.; et al. Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU). J. Infect. Dis. 2020, 222 (Suppl. S7), S658–S665. [Google Scholar] [CrossRef]
- Baraldi, E.; Bonadies, L.; Manzoni, P. Evidence on the Link between Respiratory Syncytial Virus Infection in Early Life and Chronic Obstructive Lung Diseases. Am. J. Perinatol. 2020, 37, S26–S30. [Google Scholar] [CrossRef]
- Dovizio, M.; Veronesi, C.; Bartolini, F.; Cavaliere, A.; Grego, S.; Pagliaro, R.; Procacci, C.; Ubertazzo, L.; Bertizzolo, L.; Muzii, B.; et al. Clinical and economic burden of respiratory syncytial virus in children aged 0-5 years in Italy. Ital. J. Pediatr. 2024, 50, 57. [Google Scholar] [CrossRef]
- Shiroshita, A.; Gebretsadik, T.; Wu, P.; Kubilay, N.Z.; Hartert, T.V. Association between age of respiratory syncytial virus infection hospitalization and childhood asthma: A systematic review. PLoS ONE 2024, 19, e0296685. [Google Scholar] [CrossRef] [PubMed]
- Kopera, E.; Czajka, H.; Zapolnik, P.; Mazur, A. New Insights on Respiratory Syncytial Virus Prevention. Vaccines 2023, 11, 1797. [Google Scholar] [CrossRef] [PubMed]
- American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014, 134, e620–e638. [Google Scholar] [CrossRef]
- Kato, M.; Mochizuki, H.; Kama, Y.; Kusuda, S.; Okada, K.; Yoshihara, S.; Furuya, H.; Simões, E.A.F.; Scientific Committee for Elucidation of Infantile Asthma (SCELIA). Palivizumab prophylaxis in preterm infants and subsequent wheezing/asthma: 10-year follow-up study. Pediatr. Pulmonol. 2024, 59, 743–749. [Google Scholar] [CrossRef] [PubMed]
- Azzari, C.; Baraldi, E.; Bonanni, P.; Bozzola, E.; Coscia, A.; Lanari, M.; Manzoni, P.; Mazzone, T.; Sandri, F.; Checcucci, L.; et al. Epidemiology and prevention of respiratory syncytial virus infections in children in Italy. Ital. J. Pediatr. 2021, 47, 198. [Google Scholar] [CrossRef]
- Hall, C.B.; Weinberg, G.A.; Iwane, M.K.; Blumkin, A.K.; Edwards, K.M.; Staat, M.A.; Auinger, P.; Griffin, M.R.; Poehling, K.A.; Erdman, D.; et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 2009, 360, 588–598. [Google Scholar] [CrossRef] [PubMed]
- van Summeren, J.J.G.T.; Rizzo, C.; Hooiveld, M.; Korevaar, J.C.; Hendriksen, J.M.T.; Dückers, M.L.A.; Loconsole, D.; Chironna, M.; Bangert, M.; Demont, C.; et al. Evaluation of a standardised protocol to measure the disease burden of respiratory syncytial virus infection in young children in primary care. BMC Infect. Dis. 2021, 21, 705. [Google Scholar] [CrossRef] [PubMed]
- Hartmann, K.; Liese, J.G.; Kemmling, D.; Prifert, C.; Weißbrich, B.; Thilakarathne, P.; Diels, J.; Weber, K.; Streng, A. Clinical Burden of Respiratory Syncytial Virus in Hospitalized Children Aged ≤5 Years (INSPIRE Study). J. Infect. Dis. 2022, 226, 386–395. [Google Scholar] [CrossRef] [PubMed]
- Kobayashi, Y.; Togo, K.; Agosti, Y.; McLaughlin, J.M. Epidemiology of respiratory syncytial virus in Japan: A nationwide claims database analysis. Pediatr. Int. 2022, 64, e14957. [Google Scholar] [CrossRef]
- Domachowske, J.B. New and Emerging Passive Immunization Strategies for the Prevention of RSV Infection During Infancy. J. Pediatric Infect. Dis. Soc. 2024, piae030. [Google Scholar] [CrossRef]
- Esposito, S.; Abu-Raya, B.; Bonanni, P.; Cahn-Sellem, F.; Flanagan, K.L.; Martinon Torres, F.; Mejias, A.; Nadel, S.; Safadi, M.A.P.; Simon, A. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. Front. Immunol. 2021, 12, 708939. [Google Scholar] [CrossRef] [PubMed]
- Esposito, S.; Abu Raya, B.; Baraldi, E.; Flanagan, K.; Martinon Torres, F.; Tsolia, M.; Zielen, S. RSV Prevention in All Infants: Which Is the Most Preferable Strategy? Front. Immunol. 2022, 13, 880368. [Google Scholar] [CrossRef] [PubMed]
- Esposito, S.; Amirthalingam, G.; Bassetti, M.; Blasi, F.; De Rosa, F.G.; Halasa, N.B.; Hung, I.; Osterhaus, A.; Tan, T.; Torres, J.P.; et al. Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: An update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy. Front. Immunol. 2023, 14, 1162342. [Google Scholar] [PubMed]
- Griffin, M.P.; Yuan, Y.; Takas, T.; Domachowske, J.B.; Madhi, S.A.; Manzoni, P.; Simões, E.A.F.; Esser, M.T.; Khan, A.A.; Dubovsky, F.; et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N. Engl. J. Med. 2020, 383, 415–425. [Google Scholar] [CrossRef] [PubMed]
- Muller, W.J.; Madhi, S.A.; Seoane Nuñez, B.; Baca Cots, M.; Bosheva, M.; Dagan, R.; Hammitt, L.L.; Llapur, C.J.; Novoa, J.M.; Saez Llorens, X.; et al. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. N. Engl. J. Med. 2023, 388, 1533–1534. [Google Scholar] [CrossRef] [PubMed]
- Drysdale, S.B.; Cathie, K.; Flamein, F.; Knuf, M.; Collins, A.M.; Hill, H.C.; Kaiser, F.; Cohen, R.; Pinquier, D.; Felter, C.T.; et al. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. N. Engl. J. Med. 2023, 389, 2425–2435. [Google Scholar] [CrossRef] [PubMed]
- European Medicines Agency. Beyfortus. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/beyfortus (accessed on 3 April 2024).
- HauteAuthorité de Santé. Réponses Rapides: Nirsévimab (Beyfortus®) dans la Prévention des Bronchiolites à Virus Respiratoire Syncytial (VRS) chez les Nouveau-Nés et les Nourrissons. Available online: https://www.has-sante.fr/upload/docs/application/pdf/2023-09/reponse_rapide__nirsevimab_beyfortus.pdf (accessed on 28 March 2024).
- Spanish Society of Neonatology. Recommendations of the Spanish Society of Neonatology for the Prevention of Severe Respiratory Syncytial Virus Infections with Nirsevimab, for the 2023–2024 Season. Available online: https://analesdepediatria.org/en-recommendations-spanish-society-neonatology-for-avance-S2341287923002168 (accessed on 28 March 2024).
- Levien, T.L.; Baker, D.E. Formulary Drug Reviews: Nirsevimab. Hosp. Pharm. 2024, 59, 138–145. [Google Scholar] [CrossRef] [PubMed]
- Bozzola, E.; Ciarlitto, C.; Guolo, S.; Brusco, C.; Cerone, C.; Antilici, L.; Schettini, L.; Piscitelli, A.L.; Vittucci, A.C.; Cutrera, R.; et al. Respiratory Syncytial Virus Bronchiolitis in Infancy: The Acute Hospitalization Cost. Front. Pediatr. 2021, 8, 594898. [Google Scholar] [CrossRef] [PubMed]
- Regione Valle d’Aosta. Profilassi Della Bronchiolite, al via Campagna per Neonati. Available online: https://www.ansa.it/valledaosta/notizie/2023/12/13/profilassi-della-bronchiolite-al-via-campagna-per-neonati_70a77f25-6be6-48b9-88cb-351566d0120e.html (accessed on 28 March 2024).
- Manti, S.; Staiano, A.; Orfeo, L.; Midulla, F.; Marseglia, G.L.; Ghizzi, C.; Zampogna, S.; Carnielli, V.P.; Favilli, S.; Ruggieri, M.; et al. UPDATE—2022 Italian guidelines on the management of bronchiolitis in infants. Ital. J. Pediatr. 2023, 49, 19. [Google Scholar] [CrossRef]
- Camporesi, A.; Yock-Corrales, A.; Gomez-Vargas, J.; Roland, D.; Gonzalez, M.; Barreiro, S.; Morello, R.; Brizuela, M.; Buonsenso, D. Management and outcomes of bronchiolitis in Italy and Latin America: A multi-center, prospective, observational study. Eur. J. Pediatr. 2024. [Google Scholar] [CrossRef]
- Istituto Superiore di Sanità. EpiCentro—L’epidemiologia per la Sanità Pubblica. Available online: https://www.epicentro.iss.it/influenza/2022 (accessed on 6 May 2024).
- Clopper, B.R.; Zhou, Y.; Tannis, A.; Staat, M.A.; Rice, M.; Boom, J.A.; Sahni, L.C.; Selvarangan, R.; Harrison, C.J.; Halasa, N.B.; et al. Medical Costs of RSV-associated Hospitalizations and Emergency Department Visits in Children Aged < 5 years: Observational Findings from the New Vaccine Surveillance Network (NVSN), 2016–2019. J. Pediatr. 2024, 271, 114045. [Google Scholar] [CrossRef]
- López-Lacort, M.; Muñoz-Quiles, C.; Mira-Iglesias, A.; López-Labrador, F.X.; Mengual-Chuliá, B.; Fernández-García, C.; Carballido-Fernández, M.; Pineda-Caplliure, A.; Mollar-Maseres, J.; Shalabi Benavent, M.; et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill 2024, 29, 2400046. [Google Scholar] [CrossRef] [PubMed]
- Ernst, C.; Bejko, D.; Gaasch, L.; Hannelas, E.; Kahn, I.; Pierron, C.; Del Lero, N.; Schalbar, C.; Do Carmo, E.; Kohnen, M.; et al. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Euro Surveill 2024, 29, 4. [Google Scholar] [CrossRef] [PubMed]
- Moline, H.L.; Tannis, A.; Toepfer, A.P.; Williams, J.V.; Boom, J.A.; Englund, J.A.; Halasa, N.B.; Staat, M.A.; Weinberg, G.A.; Selvarangan, R.; et al. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season—New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb. Mortal. Weekly Rep. 2024, 73, 209–214. [Google Scholar] [CrossRef] [PubMed]
- Dagan, R.; Hammitt, L.L.; Seoane Nuñez, B.; Baca Cots, M.; Bosheva, M.; Madhi, S.A.; Muller, W.J.; Zar, H.J.; Chang, Y.; Currie, A.; et al. Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season. J. Pediatric Infect. Dis. Soc. 2024, 13, 144–147. [Google Scholar] [CrossRef]
- Martinón-Torres, F.; Mirás-Carballal, S.; Durán-Parrondo, C. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023. Euro Surveill 2023, 28, 2300606. [Google Scholar] [CrossRef]
Period | Total Births | Candidates for Palivizumab | Non- Residents | Candidates for Nirsevimab | Treated with Nirsevimab | No Prophylaxis | Coverage |
---|---|---|---|---|---|---|---|
01/05/2023 18/12/2023 | 461 | 13 | 0 | 448 | 292 | 156 | 65% |
19/12/2023 15/02/2024 | 95 | 3 | 3 | 89 | 77 | 12 | 86% |
Total | 556 | 16 | 3 | 537 | 369 | 168 | 69% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Consolati, A.; Farinelli, M.; Serravalle, P.; Rollandin, C.; Apprato, L.; Esposito, S.; Bongiorno, S. Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season. Vaccines 2024, 12, 549. https://doi.org/10.3390/vaccines12050549
Consolati A, Farinelli M, Serravalle P, Rollandin C, Apprato L, Esposito S, Bongiorno S. Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season. Vaccines. 2024; 12(5):549. https://doi.org/10.3390/vaccines12050549
Chicago/Turabian StyleConsolati, Alessandra, Mariapaola Farinelli, Paolo Serravalle, Christine Rollandin, Laura Apprato, Susanna Esposito, and Salvatore Bongiorno. 2024. "Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season" Vaccines 12, no. 5: 549. https://doi.org/10.3390/vaccines12050549